AI policy with risk classes, but no documented AI responsibility at the top
Overall rating “limited”. No deduction for controversies. The superscript numbers link directly to the source.
1 · Responsibility
Novartis has published principles, a policy and a framework with risk classes, but these are unverified company statements and are not assigned to any committee or executive committee member.
What is documented
- The 2024 AI Risk & Compliance Management Framework distinguishes the classes low, medium, high and prohibited and also applies to jointly developed and purchased AI8 9
- The owner of the policy on the ethical use of data and technology is the Data Privacy, Digital and AI Compliance unit5
- According to an interview, deployment is preceded by an impact assessment and, for higher risks, an in-depth review6
- The SpeakUp channel allows anonymous reports with protection from retaliation; the figures are subject to limited assurance by KPMG3 10
- In the 20-F the implementation of AI in research is named as a separate risk factor7
The case against
Missing responsibility
No evidence of effectiveness
- The number and results of AI risk reviews and a register of AI systems in use are not published
- No external audit or certification of the AI programme was found
Sources for Responsibility (13)
- Novartis AG (SEC EDGAR, XBRL): Form 20-F FY2025, R8: Cybersecurity Risk Management and Strategy Disclosure (Item 16K) · 31 December 2025 · primary source
- Novartis AG (SEC EDGAR, Form 6-K Exhibit 99.1): Novartis Annual Report 2025 · 4 February 2026 · primary source
- Novartis AG: Report on Nonfinancial Matters 2025 · 31 December 2025 · primary source
- Novartis AG (SEC EDGAR, Form 6-K Exhibit 99.2): Report on Nonfinancial Matters 2025 (SEC filing version) · 4 February 2026 · primary source
- Novartis AG: Ethical Use of Data and Technology Policy, Version 2.0 (Public) · 3 November 2026 · secondary source
- Fieldfisher: Interview with Simon Bristow, Global Data Privacy and AI Expert, Novartis · 3 November 2026 · secondary source
- Novartis AG (SEC EDGAR): Form 20-F for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
- Novartis AG: Our commitment to ethical and responsible use of AI · 1 January 2024 · secondary source
- Novartis AG: Artificial intelligence · 3 November 2026 · secondary source
- Novartis AG: ESG Data Summary 2025 · 31 December 2025 · primary source
- Novartis AG: Code of Ethics · 3 November 2026 · secondary source
- Novartis AG: Novartis in Society Integrated Report 2024 · 31 December 2024 · secondary source
- Novartis US: Novartis US Invests in Data and AI Capabilities for 6,000 Employees · 16 September 2026 · secondary source
2 · Safety
Novartis documents a specific cybersecurity programme in its 20-F, but on the testing of AI systems there are only company statements, and a class action over tracking on product websites is pending.
What is documented
- A Chief Security Officer and a dedicated team under the CIO report figures to the executive committee; a security operations centre works around the clock4
- Simulated attacks, external tests and recovery plans are described, aligned with NIST CSF and ISO 270014
- The policy requires immediate reporting of incidents and data protection breaches6
- According to an interview, models are tested for hallucination and robustness; InfoSec sets access limits for agents3
- The 20-F names risks from AI-enhanced attacks and from AI service providers1
The case against
Missing evidence of AI testing
- No evidence of validation and monitoring of AI in trials, drug safety and manufacturing was found
- No ISO 27001 certification is stated, and AI-specific controls such as red-teaming are not described4
Sources for Safety (12)
- Novartis AG (SEC EDGAR): Form 20-F for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
- Novartis AG: Novartis Responsible Use of AI Systems · 1 October 2020 · secondary source
- McKinsey & Company: Novartis's Christian Diehl on scaling AI beyond the demo · 21 September 2026 · secondary source
- Novartis AG (SEC EDGAR, XBRL): Form 20-F FY2025, R8: Cybersecurity Risk Management and Strategy Disclosure (Item 16K) · 31 December 2025 · primary source
- Novartis AG: ESG index – Governance · 3 November 2026 · secondary source
- Novartis AG: Ethical Use of Data and Technology Policy, Version 2.0 (Public) · 3 November 2026 · secondary source
- pharmaphorum: Patient sues Novartis, claiming data-tracking privacy breach · 25 March 2026 · secondary source
- Bloomberg Law: Novartis Sued Over Tracking Pixels on Drug-Discount Websites · 24 March 2026 · secondary source
- Fierce Pharma: Novartis sued by breast cancer patient over branded drug websites' data-sharing practices · 19 March 2026 · secondary source
- JD Supra: Novartis Patient Information Leaked in Lash Group Data Breach · 22 May 2024 · secondary source
- SC World: Nearly a dozen drug firms impacted by Cencora breach · 21 February 2024 · secondary source
- Board Cybersecurity (Incident Tracker): Novartis Pharmaceuticals Cybersecurity Incident · 22 May 2024 · secondary source
3 · Transparency
Novartis commits to informing people about the use of AI and describes areas of use, but discloses neither limits nor model information for its own systems such as data42 or AE Brain.
What is documented
- The policy requires users to be informed about the use of AI and its purpose, and calls for representative training data2
- Explainability and human oversight are named as risk areas of the framework7
- Reports and announcements describe AI applications in research and development and partnerships such as the one with Isomorphic Labs4 5
The case against
No system information
- For data42, AE Brain and automated study reports, neither limits, error rates nor model information are published
- How patients and healthcare professionals are informed about the use of AI is not documented
- There is only general information on consent and anonymisation of training data8
Sources for Transparency (8)
- Novartis AG (SEC EDGAR): Form 20-F for the fiscal year ended December 31, 2025 · 31 December 2025 · primary source
- Novartis AG: Ethical Use of Data and Technology Policy, Version 2.0 (Public) · 3 November 2026 · secondary source
- Novartis AG: Novartis Responsible Use of AI Systems · 1 October 2020 · secondary source
- Novartis AG: Novartis in Society Integrated Report 2024 · 31 December 2024 · secondary source
- Pharma Focus Europe: Isomorphic Labs Announces Novartis Collaboration Expansion · 19 February 2025 · secondary source
- Novartis US: Novartis US Invests in Data and AI Capabilities for 6,000 Employees · 16 September 2026 · secondary source
- Novartis AG: Our commitment to ethical and responsible use of AI · 1 January 2024 · secondary source
- McKinsey & Company: Novartis's Christian Diehl on scaling AI beyond the demo · 21 September 2026 · secondary source
4 · Why the harm rule does not apply
The harm rule does not apply: within the window there is no judgment, authority decision or fine on harm from Novartis's AI; the tracking lawsuit and the service provider incident have no documented link to AI.
5 · Controversies (2)
- mediumAccording to a class action in New Jersey, tracking pixels on Novartis product websites passed diagnosis and prescription data to third parties without consent; no link to AI is alleged. · 19 March 2026 · open
- minorIn February 2024 data on participants in Novartis patient programmes was stolen at the service provider Lash Group (Cencora); a link to AI is not documented. · 22 May 2024 · unklar
6 · What remains open
- Board and executive committee responsibility for AI and cybersecurity after the Risk Committee was dissolved
- Figures on the AI programme, such as the number of reviews, high-risk systems and prohibited applications
- Evidence of validation and monitoring of AI in trials, drug safety and manufacturing
- Status of and remedy in the tracking lawsuit
- Governance and legal chapters of the 2025 20-F and annual report, which were truncated on retrieval
7 · How it was assessed
Cut-off date: 3 November 2026 · 43 searches, 41 fetches.
Primary documents read (11)
- Form 20-F FY2025 (Risk Factors) and XBRL R8 (Item 16K), R28, R35
- Annual Report 2025 (to p. 23)
- Report on Nonfinancial Matters 2025 (novartis.com and SEC version)
- ESG Data Summary 2025
- Novartis in Society Integrated Report 2024
- Interim Reports Q1 2026 and Q3 2026 (Form 6-K)
- Ethical Use of Data and Technology Policy v2.0
- Our commitment to ethical and responsible use of AI
- Responsible Use of AI Systems (2020)
- Code of Ethics
- AGM 2026 Press Release
Research of 3 November 2026 under Globalance AI Footprint rulebook version 0